ASCO 2023

Discussions and controversies on social-media: what is the impact of science-twitter discussions on the everyday practice in oncology?

ADC revolution: How can the new results be integrated in clinical practice? Which studies are in sight and which ones do we need in the future?

CDK4/6i in EBC: Have abema and ribo arrived in the early setting? Insights from North America and Europe

Sonia trial: How does the new data change clinical practice - or does it at all? Insights from Italy, United States and Germany.

CDK4/6 inhibitors in EBC: Amazing data, but longer follow up needed!

Expanding CDK4/6i therapy in EBC: How to select patients for the right therapy?

PART1: How to de-escalate chemotherapy? What is the best strategy to identify patients who don´t need chemotherapy?

PART2: Trying to understand optimal therapy for pre-menopausal women - promising results, but still long way to go!

Chemotherapy de-escalation in HER2+ patients: Consequences of the PHERGain data on daily practice?!

New data on Ribocilib in adjuvant setting EBC: What does it change immediately, what changes are expected in the future? Perspectives from Europe and Northern America

Data from Meta-Analyses of almost 15k Patients: Who benefits from ovarian function suppression?

Practice changing or not quite yet?

Palbociclib after Palbociclib might not be the best option

De-escalation of CT for early BC

TILs subtypes are associated with clinical features and prognosis in HR+/HER2- BC

White blood cells with increasing prognostic relevance? Data from the GeparNuevo Study

1/3 of patients with HER2+ in future without chemotherapy?

Can we preserve our patients form chemotherapy?

Chemo-immunotherapeutic signals especially in HER2low possibly predictive of chemotherapy response in EBC

Discussions on CDK4/6 inhibitors in EBC

Ribociclib has arrived in the adjuvant setting

Ovarian function - Ovarian suppression not necessary in young patients?

My EBC highlights from ASCO23

Young patients benefit from ovarian suppression

From PENELOPE-B to SURVIVE

Response adapted, chemotherapy-free option in HER2+ EBC

Checkpoint inhibition in endometrial cancer: new therapy algorithms needed

Early follow-up shows clear benefit

More CDK4/6 options for EBC patients

Tumor-informed ctDNA likely prognostic for relapse in ER positive and HER2 negative EBC

TILs are prognostic but not predictive in HER2+ EBC

Another proof of efficacy of immunotherapy in advanced TNBC

Analyses of ctDNA in PENELOPE-B: Test methods are increasingly accurate

TILs in HER2+ disease - prognostic, but not enough to deescalate

10 years update on ShortHER

Ribociclib improves iDFS

SOC of ovarian ablation confirmed in meta-analysis.

PHERGain opens the possibility to avoid chemotherapy in HER2+ breast cancer

A challenge for clinical management

First data with adjuvant ribociclib

SOC der ovarialen Ablation in der Metaanalyse bestätigt

Ovar Funktion - Ovarielle Supression verzichtbar bei jungen Patientinnen?

Eine Herausforderung für viele Patienten, wenig Doktoren

Primele date cu ribociclib adjuvant

Palbociclib después de Palbociclib podría no ser la mejor opción

PHERGain abre la posibilidad de evitar la quimioterapia en el cáncer de mama HER2+

Eine Herausforderung für das klinische Management

Czy wystarczy, aby zmienić standardy?

I miei punti salienti di ASCO23

TILs w rakach HER2+ - znaczenie rokownicze, ale nie droga do deeskalacji leczenia

1/3 der Patientinnen mit HER2+ zukünftig ohne Chemotherapie?

Kolejny dowód na skuteczność immunoterapii w zaawansowanym raku trójujemnym

Chemo-IO Signale bei HER2low prädiktiv für Ansprechen der Chemotherapie

TILs Subtypen sind assoziiert mit klinischen Merkmalen und Prognose beim HR+/HER2- BC

Tumor-informed ctDNA wahrscheinlich prognostisch für einen Rückfall beim ER positive und HER2 negative eBC

Von PENELOPE-B zur SURVIVE

NATALEE nicht überraschend aber überzeugend positiv

TILs sind prognostisch aber nicht prädiktiv beim HER2+ eBC

Response adaptierte, Chemotherapie-freie Option beim HER2+ eBC

Continued OS benefit for Sacituzumab Govitecan

The start of precision medicine in HR+ breast cancer

Molecular imaging for endocrine responsivness

CDK4/6 i beyond CDK4/6 i: one more piece to the puzzle

What is the optimal therapie sequence for HR+ MBC patients?

E-Health Applications in Oral Cancer Therapy

Updates on ADCs in metastatic breast cancer

CDK4/6i dopo CDK4/6i, un altro pezzo del puzzle: lo studio PALMIRA

Mises à jour sur les ADC dans le cancer du sein métastatique

Aggiornamenti sugli ADC nel carcinoma mammario metastatico

CDK4/6i in first line and beyond & Biomarkers

CDK4/6 Sequencing? ESR-1 not ready for prime time? Palbo rechallenge?

Update ADC efficacy

The value of eHealth

DEAR trial: real-world comparator analyses of ARIs

TALAPRO-2: Results and controversies

PEACE 1 - results and controversies

Part 1: Important update on testosterone-recovery

PAPR-inhibitors: Patient-selection matters!

Confirming results for PARPi in mCRPC

LuPARP combination study: LuPSMA and Olaparib in mCRPC

ARASEC: ADT + Daralutamide for mHSPC

AI for prediction in local prostate carcinoma

PRL-02: Intramuscular arbiraterone

Intensified or de-intensified therapy in mHSPC

Metastasis-directed for prostate cancer

Part2: Important update on testosterone-recovery

Over-staging of bone scan compared with PSMA PET/CT

PSA nadir 6 month after Radiotherapy is strong prognostic marker for survival

Reassuring real-world data!

Intensifierad eller de-intensifierad behandling vid mHSPC?

PSA nadir 6 månader efter radioterapi är en prognostisk markör för överlevnad

Επιβεβαίωση αποτελεσμάτων για το PARPi στο mCRPC

PARP-inhibitors: La selección de pacientes es importante

LuPARP studien: 177-Lu-PSMA och olaparib vid mCRPC

Skelettscintigrafi ospecifikt jämfört med PSMA PET-CT

PARPi in PCa: more genetic testing is required as PRO data demand better patient selection

Triple therapy in mCSPC - which is the ideal partner for radiotherapy? And which patients should received irradiation?

What is your preferred sequence in 1st line treatment and how you treat after progress?

The beginning of a new era in urothelial cancer?!

Q-TWiST in the therapy of aUC

Best of Bladder: ddMVC increases DFS! Standard dissection SOC? FGFR targeting showing efficacy!

Targeted therapies in advanced urothelial cancer: The renaissance?!

Enfortumab vedotin + pembrolizumab 1stL in cisplatin-ineligible patients

First line in cisplatin-ineligible advance urothelial cancer: It´s getting busy out there

New standard for MIBC

Extent of lymphadenectomy in cystectomy

New SoC option for metastatic bladder cancer

FGFR inhibition

Best of Bladder: ddMVC increases DFS! Standard dissection SOC? FGFR targeting showing efficacy!

Terapias dirigidas al cáncer urotelial avanzado: ¡¿El renacimiento?!

Primera línea en cáncer urotelial avanzado no elegible para cisplatina: Hay mucho trabajo ahí fuera

Nouvelles options de soins standard pour le cancer de la vessie métastatique

The efficacy of neo-adjuvant therapy (ddMVAC, Cisplatinum)

The efficacy of FGFR targeting

Update EV/Pembro, Avelumab Maintenance

Long term follow up in advanced renal cell cancer: Is everything clear, yet?

Non ccRCC: how should we treat patients today?

The impact of microbiome and supplements on therapy efficacy

Primary endpoint not reached: what do we learn from CONTACT-03 results?

New standard for 2nd line RCC?

Update and take home message of 1st Line mRCC

New data non ccRCC

Long-term follow-up for IO/TKI in mRCC

News from the adjuvant

IO rechallenge in mRCC

1st Line therapy RCC: which combination to choose?

Lenvatinib + pembrolizumab in non-clear cell renal cell carcinoma

ADAURA: Osimertinib improves survival in the treatment of EGFRm rNSCLC

The value of perioperative chemo-IO in rNSCLC and the importance of staging

EGFR testing necessary in the adjuvant setting

An imperfect analysis, but perfect results

Role of periopertative IO confirmed

ADAURA - results and controversies

Which should we prefer: neoadjuvant, adjuvant or perioperative chemo/IO?

Perioperative treatment

OS benefit from EGFR receptor TKI

Another neoadjuvant chemo/IO option

Added benefit of perioperative chemo/IO in stage 2-3b NSCLC

ADAURA - Discussion closed?

Induction options in the perioperative setting

Confirmation of neoadjuvant immunotherapy

A new standard of care for operated patients with eGFRmut adenocarcinoma

A chemo-free preop. IO strategy?

More options in the perioperative setting

Adjuvant IO in KRASm patients

A new standard of care

Adjuvant and neoadjuvant strategies in resectable NSCLC

CheckMate 9LA: 4‑year clinical update

Más opciones en el entorno perioperatorio

Que devrions-nous préférer: traitement néoadjuvant, adjuvant ou chimio/IO périopératoire?

Un nouveau standard therapeutique pour les patients opérés d’un adenocarcinome EGFR muté

Stratégies adjuvantes et néoadjuvantes dans le CBNPC résécable

Rolle der periopertativen IO bestätigt

Toegevoegde waarde van periperatief chemo-immuno bij stadium II-IIIB NSCLC

ADAURA- discussie gesloten?

Does ADC + chemo + IO replace the existing concepts?

TTF-treatment requires further studies

Sotorasib: clear clinical benefit, but short follow-up time

Zorifertinib: an option when osimertinib is not available

Pembro + chemo in pts with TKI-resistant EGFRm / Sunvozertinib - a drug for Exon20 insertions

Update on KRASG12Cm treatment options - how to proceed?

Stopping treatment is ok

TROP2-ADC shows high response rates in 1L-combination therapy, but safety must be observed

ADC + ICI ± Pt-CT in patients with aNSCLC

CORRELATE - a real world analysis

IO in EGRF positive patients post TKI

LUNAR: TTF medical device shows OS-benefit, but more information needed

Hyperfractionation - an interestingh concept, but not for every patient

New data from another BiTE

Treatment strategies in SCLC

A positive trial with no impact

Hyperfractionated radiotherapy for SCLC

More BiTEs, more possibilities

Can we incoporate biomarkers in SCLC treatment?

Stratégies de traitement dans le SCLC

Más BiTEs, más posibilidades

Kunnen we biomarkers gebruiken om behandeling te selecteren voor SCLC?

No practice-changing data in mesothelioma, other studies to await

ONCOalert (inclusive patient advocates) consensus on the results of the PROspect trial

Immune checkpoint inhibitors in malignant mesothelioma

Immun-Checkpoint-Inhibitoren beim malignen Mesotheliom